Session Type: Poster Session
Date: Monday, June 6, 2022
Time: 8:00-11:00 a.m. CDT
This is the first breast cancer risk model to include breast density, family history and a polygenic risk score (PRS) based on genetically determined ancestry that is validated for diverse populations. The addition of PRS substantially improved risk stratification over TCv8 alone and may allow for a more personalized approach to breast cancer risk reduction.
Session Type: Poster Discussion
Time: 4:30-6:00 p.m.; 1:15-4:15 p.m. CDT
In this population of women who had multigene panel testing, pathogenic variants in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, and BARD1 were associated with substantial risk of triple-negative breast cancer (TNBC). There were no significant differences in pathogenic variant associated TNBC risks across ancestries. TNBC was reported more frequently in women of African ancestry.
This exploratory analysis evaluated the ability of ≥ 33 or ≥ 42 genomic instability score (GIS) thresholds to predict response to platinum-based treatment in patients with triple-negative breast cancer. This study of 204 tumors of mixed BRCA wild-type, BRCA mutations and unknown showed that a GIS of ≥ 33 may be the most appropriate threshold to predict response to platinum-based treatment in patients with TNBC; however, a prospective trial is needed.
Time: 8:00 -11:00 a.m. CDT
In this cohort of patients, even when accounting for other clinical factors such as node status, tumor grade, age at diagnosis, and other variables, Myriad’s EndoPredict® Breast Cancer Prognostic Test provided significant information for clinical decisions on extended endocrine therapy.
Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive results for comprehensive germline testing, tumor profiling and companion diagnosic options, including HRD† testing with one order.
† For patients with ovarian cancer